Detail akcie MoonLake Imm Rg-A online

Business Summary: MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, MoonLake Immunotherapeutics revenues was not reported. Net loss increased from $73.3M to $164.9M. Higher net loss reflects operating segment loss increase of 92% to $179.6M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.17 to -$2.60.